Premium
Preoperative Cervical Dilatation with 15(S)15‐Methyl PGF 2 α Methyl Ester Pessaries
Author(s) -
Chatterjee Tapan K.,
Grech Edwin S.,
Niles Lalitha
Publication year - 1978
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/j.1879-3479.1977.tb00724.x
Subject(s) - medicine , cervical dilatation , gynecology , cervix , cancer
A clinical trial comparing two vaginal dose schedules of 15(S)15‐methyl prostaglandin F 2 α (PGF 2 α ) methyl ester (4 or 6 mg) for preoperative dilatation of the cervix is described. The trial included 28 patients at 8–12 weeks' gestation. Vaginal pessaries containing either 1.0 mg (15 patients) or 1.5 mg (13 patients) of the prostaglandin analogue were administered every 3 hours (maximum, 4 doses). The success rates for the two groups were 93% and 100%, respectively. Sixty percent of the patients aborted before the planned vacuum aspiration. Minor side effects, primarily vomiting and diarrhea, occurred in approximately 80% of the cases and were more prominent with the higher dose pessary. It is concluded that the vaginal administration of 15(S)15‐methyl PGF 2 α methyl ester is highly effective for preoperative dilatation of the cervix before suction curettage abortion.